γ/δ T cells have stimulated a lot of interest because of their unique features in antigen recognition and cytotoxicities to many autologous and/or allogeneic tumor cells. We have developed a novel method to selectively expand larger amounts of human tumor–infiltrating γ/δ T lymphocytes (γ/δ TILs) ex vivo by immobilized pan– anti–TCRγ/δ monoclonal antibody in the presence of exogenous IL–2. The expanded γ/δ TILs mainly expressed CD45RO and HLA–DR molecules and did not express CD4. CD8+ γ/δ TILs accounted for 19% of γ/δ TILs. The expression of CD25 molecule on expanded γ/δ T cells was inducible and downregulated following a time course. The Vδ1 and Vδ2 subsets amount to 37 and 58%, respectively. The expanded γ/δ TILs show an IL–2–dependent proliferation, MHC class I–unrestricted and TCRγ/δ–related cytotoxicities to two MHC class I+ and two MHC class I+ allogeneic tumor cell lines in vitro.

Keywords:
Gamma/Delta T lymphocytes, Tumor infiltrating lymphocytes, MHC restriction, Cytotoxicity, Tumor
1.
Haas W, Pereila P, Tonegawa S: Gamma/Delta T cells. Annu Rev Immunol 1993;11:637–685.
2.
Raulet DH: The structure, function and molecular genetics of the gamma/delta T cell receptor. Annu Rev Immunol 1989;7:175–207.
3.
Schild H, Mavaddat N, Litzenberger C, Ehrich EM, Davis MM, Bluestone JA, Matis L, Draper RK, Chien YH: The nature of major histocompatibility complex recognition by γ/δ T cells. Cell 1994, p 29.
4.
Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczak K, Rabinowich H, Duquesnoy R, Storkus W, Lotze MT: Human intestinal Vδ1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996;183: 1681.
5.
Kowalczyk D, Skorupski W, Drews M, Nowak J: Different pattern of T cell receptor delta gene rearrangement in tumour–infiltrating lymphocytes and peripheral blood in patients with solid tumours. Cancer Immunol Immunother 1994;39:275.
6.
Ferrarini M, Heltai S, Chiesa G, Sabbadini MG: V delta 1+ gamma/delta T lymphocytes infiltrating human lung cancer express the CD8 alpha/alpha homodimer. Scand J Immunol 1994;40:363–367.
7.
Zocchi MR, Ferrarini M, Casorati G: T–cell receptor Vδ gene usage by tumor reactive γδ T lymphocytes infiltrating human lung cancer. Immunology 1994;81:234–239.
8.
Kitayama J, Atomi Y, Nagawa H, Kurado A, Mutoh T, Minami M, Juji T: Functional analysis of TCR γ/δ+ T cells in tumor–infiltrating lymphocytes (TIL) of human pancreatic cancer. Clin Exp Immunol 1993;93:442–447.
9.
Pearcy C, van Holten V, Muir C (eds): International Classification of Disease for Oncology, ed 2. Geneva, WHO, 1990.
10.
Kabelitz D: Human γ/δ T lymphocytes. Int Arch Allergy Immunol 1993;102:1–9.
11.
Viale O, van der Bruggen P, Meuer E, Kunzmann R, Kohler H, Mertelsmann R, Boon T, Fisch P: Recognition by human Vγ9/Vδ2 T cells of melanoma cells upon fusion with Daudi cells. Immunogenetics 1996;45:27–34.
12.
Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H: Vγ9/Vδ2 TCR–dependent recognition of non–peptide antigens and Daudi cells analysis by TCR gene transfer. J Immunol 1995;154:998–1006.
13.
Hanrahan CF, Kimpton WG, Howard CJ, Parsons KR, Brandon MR, Andrews AE, Nash AD: Cellular requirements for the activation and proliferation of ruminant gamma delta T cells. J Immunol 1997;159:4287–4294.
14.
Ferrick DA, Schrenzel MD, Mulvania T, Hsieh B, Ferlin WG, Lepper HD: Differential production of interferon–γ and interleukin–4 in response to Th1– and Th2–stimulating pathogens by γδ T cells in vivo. Nature 1995;373:255– 257.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.